ACL — Australian Clinical Labs Cashflow Statement
0.000.00%
- AU$599.38m
- AU$893.53m
- AU$696.37m
- 84
- 76
- 40
- 73
Annual cashflow statement for Australian Clinical Labs, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 0.037 | 0.075 | 0.045 | 0.182 | 0.501 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | 102 | 154 | 284 | 144 | 160 |
Capital Expenditures | -9.38 | -9.51 | -21.3 | -6.93 | -6.5 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -0.577 | 3.43 | -50.8 | -5.25 | -0.742 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -9.96 | -6.08 | -72 | -12.2 | -7.25 |
Financing Cash Flow Items | — | -216 | -0.061 | 0 | -0.388 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -60.9 | -147 | -221 | -138 | -146 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 30.7 | 0.384 | -8.86 | -6.42 | 6.18 |